^
    2d
    BALDER: Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, medac GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jakafi (ruxolitinib)
    5d
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2027 --> Nov 2026
    Trial primary completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    6d
    IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy. (PubMed, Front Immunol)
    This mechanism of antigen loss can be rescued with anti-IFNγ neutralizing antibody, the JAK inhibitor ruxolitinib, or 4-phenylbutyrate (an ER stress reliever). We revealed a negative effect of IFNγ that uniquely interferes with immunotherapies targeting native surface antigens, such as CART and BiTE therapies, which may be reversed by disrupting stress signaling pathways to enhance solid tumor CART and BiTE immunotherapies.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • GUCY2C (Guanylate Cyclase 2C)
    |
    Jakafi (ruxolitinib)
    6d
    Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently. (PubMed, NPJ Precis Oncol)
    In contrast, other JAK-STAT3 inhibitors such as ruxolitinib and knockdown of STAT3 does not replicate this effect, indicating that the anti-tumor effect of filgotinib is independent of JAK-STAT3 signaling. This study offers innovative insights and potential therapeutic strategies for the treatment of PDAC through EIF3A m6A.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • EIF6 (Eukaryotic Translation Initiation Factor 6) • METTL3 (Methyltransferase Like 3)
    |
    Jakafi (ruxolitinib)
    6d
    cHL-PG01: A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL) (2024-520123-83-01)
    P1/2, N=48, Active, not recruiting, Universita' Degli Studi Di Perugia | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Keytruda (pembrolizumab) • Jakafi (ruxolitinib) • Adcetris (brentuximab vedotin)
    7d
    Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management. (PubMed, Chin Med J (Engl))
    For management, we evaluate conventional therapies (corticosteroids, etoposide) and emerging immunomodulatory agents (anakinra, ruxolitinib, emapalumab), emphasizing the 2023 treatment regimen by the American Society of Transplantation and Cellular Therapy (ASTCT). By integrating risk stratification, early diagnostic criteria, and tailored therapeutic approaches, this review aims to improve clinical outcomes for IEC-HS patients.
    Journal • IO biomarker
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • CRP (C-reactive protein)
    |
    TET2 mutation
    |
    Jakafi (ruxolitinib) • etoposide IV • Kineret (anakinra)
    7d
    Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report. (PubMed, Front Immunol)
    Treatment with hydroxycarbamide and ruxolitinib resulted in decreased platelet counts and improved vasculitis, with no subsequent recurrence of cardiovascular events. This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with JAK2 mutation-positive ET.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib) • hydroxyurea
    7d
    Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery. (PubMed, Pharm Sci Adv)
    Over the past two decades, the field has progressed from the identification of early JAK2 inhibitors to the approval of several first-generation agents, including ruxolitinib, tofacitinib, baricitinib, and fedratinib, which validated the clinical feasibility of JAK blockade. Together, these multidisciplinary approaches have accelerated hit discovery, refined selectivity, and improved the pharmacokinetic and safety profiles of emerging JAK inhibitors. By consolidating progress across medicinal chemistry, structural biology, and computational design, this review outlines key opportunities and remaining challenges in developing next-generation JAK inhibitors with enhanced precision and therapeutic value for oncology, immunology, and chronic inflammatory diseases.
    Review • Journal
    |
    JAK3 (Janus Kinase 3)
    |
    Jakafi (ruxolitinib) • Inrebic (fedratinib) • tofacitinib
    7d
    NCI-2013-00704: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=121, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Jan 2026 | Trial primary completion date: Apr 2027 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    azacitidine • Jakafi (ruxolitinib)
    8d
    DIONE-01: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, iOnctura | Trial completion date: Mar 2025 --> Mar 2027
    Trial completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF mutation • BRAF V600 • ALK translocation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    cisplatin • Bavencio (avelumab) • Jakafi (ruxolitinib) • pemetrexed • roginolisib (IOA-244)
    8d
    P30CA015704: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=61, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    8d
    A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Suzhou Junjing BioSciences Co., Ltd. | Recruiting --> Active, not recruiting | N=49 --> 33
    Enrollment closed • Enrollment change
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)